Related Experiment Videos
Radioimmunoscintigraphy in patients with ovarian cancer
H P Kalofonos1, M V Karamouzis, A A Epenetos
1Department of Medicine, University Hospital of Patras, Rion, Greece. kalofon@med.upatras.gr
Abstract:
The use of radiolabeled monoclonal antibodies (MoAbs) has significantly improved the ability to detect tumor antigens, thus improving in vivo tumor diagnosis and treatment. The management of ovarian carcinoma still poses a challenging medical problem. Clinical trials using radioimmunoscintigraphy or a hand-held gamma detection probe intraoperatively were performed in patients with clinical evidence of primary or recurrent ovarian cancer. Immunoscintigraphy of ovarian cancer lesions has been performed mainly with 99mTc, 111In and 123I labeled with HMFG1, HMFG2, OC-125, B72.3, H17E2, OVTL3, MoAb170, Mov18 and other MoAbs. Antibody guided imaging using radioimmunoscintigraphy has demonstrated improved targeting of ovarian cancer, resulting in a highly sensitive and specific method. However, it is not yet known which type of MoAb is the most efficient for radioimmunoscintigraphy. Since these tumors represent a potentially curable disease, radioimmunoscintigraphy could contribute mainly to accurate staging as a supplementary to conventional diagnostic methods, as well as for the localization of active disease after chemotherapy and monitoring for the presence of recurrent disease. Nevertheless, prospective studies in a large number of patients should be undertaken in order to further evaluate the diagnostic contribution of this approach.
Insights
Radioimmunoscintigraphy using radiolabeled monoclonal antibodies (MoAbs) shows promise for ovarian cancer diagnosis and staging. Further studies are needed to determine the most effective MoAb for this sensitive and specific imaging technique.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunology
Background:
- Ovarian carcinoma management remains challenging.
- Radiolabeled monoclonal antibodies (MoAbs) enhance in vivo tumor antigen detection for diagnosis and treatment.
- Radioimmunoscintigraphy offers a sensitive and specific method for ovarian cancer imaging.
Purpose of the Study:
- To evaluate the utility of radioimmunoscintigraphy and intraoperative gamma detection probes in diagnosing primary or recurrent ovarian cancer.
- To assess the potential of antibody-guided imaging for improving ovarian cancer staging and monitoring.
- To identify the most efficient monoclonal antibody for radioimmunoscintigraphy in ovarian cancer.
Main Methods:
- Clinical trials involving radioimmunoscintigraphy and intraoperative gamma detection probes.
- Utilizing various radiolabeled MoAbs (e.g., HMFG1, OC-125, B72.3) with radioisotopes (e.g., 99mTc, 111In, 123I).
- Imaging of ovarian cancer lesions in patients with suspected or recurrent disease.
Main Results:
- Radioimmunoscintigraphy demonstrated improved targeting of ovarian cancer.
- The technique proved to be highly sensitive and specific for detecting ovarian cancer lesions.
- The optimal MoAb for radioimmunoscintigraphy in ovarian cancer has not yet been determined.
Conclusions:
- Radioimmunoscintigraphy can aid in accurate staging of ovarian cancer as a supplementary diagnostic tool.
- This imaging approach can help localize active disease post-chemotherapy and monitor for recurrence.
- Prospective, large-scale studies are necessary to fully establish the diagnostic value of radioimmunoscintigraphy for ovarian cancer.